IL175535A - Compositions for treatment of neurodegenerative diseases - Google Patents

Compositions for treatment of neurodegenerative diseases

Info

Publication number
IL175535A
IL175535A IL175535A IL17553506A IL175535A IL 175535 A IL175535 A IL 175535A IL 175535 A IL175535 A IL 175535A IL 17553506 A IL17553506 A IL 17553506A IL 175535 A IL175535 A IL 175535A
Authority
IL
Israel
Prior art keywords
preparations
treatment
neurodegenerative diseases
neurodegenerative
diseases
Prior art date
Application number
IL175535A
Other languages
English (en)
Hebrew (he)
Other versions
IL175535A0 (en
Inventor
Michal Eisenbach-Schwartz
Jonathan Kipnis
Ester Yoles
Oleg Butovsky
Original Assignee
Yeda Res & Dev
Michal Eisenbach-Schwartz
Jonathan Kipnis
Ester Yoles
Oleg Butovsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Michal Eisenbach-Schwartz, Jonathan Kipnis, Ester Yoles, Oleg Butovsky filed Critical Yeda Res & Dev
Priority to IL175535A priority Critical patent/IL175535A/en
Publication of IL175535A0 publication Critical patent/IL175535A0/en
Publication of IL175535A publication Critical patent/IL175535A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL175535A 2003-11-12 2006-05-10 Compositions for treatment of neurodegenerative diseases IL175535A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL175535A IL175535A (en) 2003-11-12 2006-05-10 Compositions for treatment of neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51862703P 2003-11-12 2003-11-12
US61096604P 2004-09-20 2004-09-20
PCT/IL2004/001037 WO2005046719A1 (en) 2003-11-12 2004-11-11 Vaccine and method for treatment of neurodegenerative diseases
IL175535A IL175535A (en) 2003-11-12 2006-05-10 Compositions for treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
IL175535A0 IL175535A0 (en) 2006-09-05
IL175535A true IL175535A (en) 2016-03-31

Family

ID=34594916

Family Applications (2)

Application Number Title Priority Date Filing Date
IL175535A IL175535A (en) 2003-11-12 2006-05-10 Compositions for treatment of neurodegenerative diseases
IL224393A IL224393B (en) 2003-11-12 2013-01-24 Compositions for treatment of huntington's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL224393A IL224393B (en) 2003-11-12 2013-01-24 Compositions for treatment of huntington's disease

Country Status (7)

Country Link
US (3) US20080085269A1 (enExample)
EP (2) EP1684797A1 (enExample)
JP (1) JP5456235B2 (enExample)
AU (1) AU2004288654B2 (enExample)
CA (1) CA2546077C (enExample)
IL (2) IL175535A (enExample)
WO (1) WO2005046719A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2005056574A2 (en) 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
EP1684797A1 (en) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
EP2195008A1 (en) 2007-09-24 2010-06-16 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
WO2010019270A1 (en) * 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation of prion expression
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
WO2013055683A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2013059322A2 (en) * 2011-10-17 2013-04-25 Lawrence Steinman Amyloid beta peptide as a therapy for inflammation
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN114081946A (zh) * 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
WO2017201539A1 (en) 2016-05-20 2017-11-23 Cedars-Sinai Medical Center Methods of treating or preventing alzheimer's disease and associated conditions
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
LT3506921T (lt) 2016-08-31 2023-08-10 Mapi Pharma Ltd Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
MX2021005886A (es) 2018-11-21 2021-06-23 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de priones.
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
IL140592A0 (en) 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
HK1054507B (zh) * 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
IL150801A0 (en) * 2000-06-07 2003-02-12 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
YU89503A (sh) 2001-05-17 2006-05-25 Applied Research System Ars Holding N.V. Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti
US7718699B1 (en) 2005-03-04 2010-05-18 Broyles Robert H Abscissic acid and derivatives thereof for the treatment of diseases
RU2303996C2 (ru) 2001-12-06 2007-08-10 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Вакцина и способ лечения болезней двигательных нейронов
EP1684797A1 (en) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US7220729B2 (en) 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment

Also Published As

Publication number Publication date
AU2004288654B2 (en) 2009-12-03
CA2546077A1 (en) 2005-05-26
JP2007513079A (ja) 2007-05-24
IL224393B (en) 2018-06-28
CA2546077C (en) 2016-07-05
EP2301569A2 (en) 2011-03-30
US20140134196A1 (en) 2014-05-15
US20080085269A1 (en) 2008-04-10
AU2004288654A1 (en) 2005-05-26
EP2301569B1 (en) 2018-05-02
WO2005046719A1 (en) 2005-05-26
US9517256B2 (en) 2016-12-13
US8828404B2 (en) 2014-09-09
EP2301569A3 (en) 2011-07-06
EP1684797A1 (en) 2006-08-02
JP5456235B2 (ja) 2014-03-26
US20110206706A1 (en) 2011-08-25
IL175535A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
IL175535A (en) Compositions for treatment of neurodegenerative diseases
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
FI20060154L (fi) Neurogeneratiivisten tilojen hoito
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
SE0502484L (sv) Behandling av neurodegenerativa tillstånd
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
PL1708991T3 (pl) Pochodne sulfonoamidu do leczenia chorób
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
GB0329874D0 (en) Compounds useful for the treatment of diseases
EP1611120A4 (en) NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
DK1597171T3 (da) Terapeutisk mikroskum
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DE60315490D1 (de) Therapeutische behandlung

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed